UTHR (Biotechnology) Stock Valuation & Fair Value Quality business at a reasonable price
UTHR (Biotechnology) trades at a blended P/E of 19.1, about 20% below its historical normal valuation, with a forward growth estimate of 18.5% and a PEG of 1.04. Analysts' one-year estimates have been hit 36% of the time.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is UTHR overvalued?
At a blended P/E of 19.1 versus its historical normal P/E of 23.8, UTHR trades about 20% below its typical valuation, with a PEG of 1.04 on 18.5% forward growth. tickerseer currently rates it quality business at a reasonable price.
What is UTHR's fair value and PEG?
UTHR trades at a blended P/E of 19.1 against a historical normal P/E of 23.8, a PEG of 1.04, and a forward growth estimate of 18.5%.
Has tickerseer's rating of UTHR changed?
tickerseer's rating has been quality business at a reasonable price since 2026-07-31.
Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.